RESUMO
Coronavirus disease 2019 (COVID-19) usually presents as a respiratory infection, and may progress to multiple organ failure and eventually death. In COVID-19 patients, kidney dysfunctions reported proteinuria, elevated markers of blood urea nitrogen, plasma creatinine, uric acids, and D-dimer. We present here the case of a 49-year-old male who was admitted to the intensive care unit (ICU) with COVID-19 pneumonia and respiratory failure. Diabetes insipidus (DI) developed during intensive care follow-up without electrolyte imbalance or kidney failure. A contrast-enhanced brain and pituitary MRI was performed to identify the etiology of the central DI, but revealed no pathological findings. The drugs used to treat our patient had no polyuria side effects. No electrolyte imbalance was identified from a blood test of our patient, and there were no findings of other diseases in the differential diagnosis that could lead to nephrogenic DI. We present here a case of COVID-19 infection complicated by nephrogenic diabetes insipidus, given the lack of reports in literature indicating the occurrence of diabetes insipidus alongside COVID-19 infection.
RESUMO
Objective: SuPAR is known as a marker for inflammation. In this study, we aimed to analyse suPAR levels and its correlation with disease prognosis in COVID-19 patients. Method: Demographical, clinical and laboratory data of the 36 patients were recorded. Existence of suPAR levels and other parameters along with prognosis was studied. Result: Of 36 patients included in this study, 15 were female (42%) and 21 were male (58%). The median age of the patients with mortality was 73 (min-max ,IR;49-88, 25), and the median age of the patients with no mortality was 72 (min-max ,IR;47- 83, 21) revealing a statistically non-significant difference (p=0,596). Among lab tests, hemoglobin (p=0,044), urea (p=0,011), troponin(p=0,033), LDH (p=0,005), and procalcitonin (p=0,036) were significantly associated with mortality. Median suPAR level was 102 (min-max, IR;29-540, 274) for the patients with no mortality whereas, median suPAR level was 61 (min-max, IR;29-540, 355) for the patients with mortality, and the difference was statistically non-significant (p=0,607). Conclusion: SuPAR levels seem to be ineffective to predict disease severity and prognosis of COVID-19. More randomised controlled trials with larger groups are needed to clarify the association of suPAR levels and COVID-19. © 2021 A. CARBONE Editore. All rights reserved.
RESUMO
Objective: The aim of this study was to investigate the efficacy of favipiravir (FVP) in severe COVID-19. Methods: This is a retrospective study of 142 COVID-19 patients with severe pneumonia signs, who received inpatient treatment between March 15 and May 20, 2020. The patients were divided into two groups according to the use of FVP treatment;group 1 (n = 99) included patients who treated with FVP and group 2 (n = 43) who didn't receive FVP. Results: Mean age was 66.47 +/- 11.89 in group 1, and 68.58 +/- 14.78 in group 2. Forty patients (40.4%) in group 1 and 22 (51.2%) in group 2 were treated in the intensive care unit (P > 0.05). The proportion of eosinophil, tendency of increasing thrombocyte counts and eosinophil/neutrophil ratio in FVP group was significantly higher than non-FVP group (p < 0.05). In Group 1, patients had significantly reduced erythroid series, and elevated uric acid levels as side effects of FVP. With respect to complications during hospitalization, there was no significant difference among the groups for mechanical ventilator requirement, acute kidney injury, dialysis requirement and sepsis (P > 0.05). The mortality rates in Group 1 (n = 26 [26.3%]) were lower than those in group 2 (n = 16 [37.2%]), but it was not statistically significant. Conclusions: While the treatment of COVID-19 pneumonia options were limited during the initial stages of the pandemic, the FVP may be effective in severe cases. To confirm this effect, randomized controlled studies are needed in patients of all disease severities.